MaxCyte, Inc. (MXCT)

Market Cap	392.57M
Revenue (ttm)	41.29M
Net Income (ttm)	-37.92M
Shares Out	104.13M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	477,877
Open	3.950
Previous Close	3.830
Day's Range	3.740 - 3.950
52-Week Range	2.450 - 5.545
Beta	1.04
Analysts	Strong Buy
Price Target	8.67 (+129.97%)
Earnings Date	May 7, 2024

About MXCT

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engin...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 143
• Stock Exchange: NASDAQ
• Ticker Symbol: MXCT

Financial Performance

In 2023, MaxCyte's revenue was $41.29 million, a decrease of -6.72% compared to the previous year's $44.26 million. Losses were -$37.92 million, 60.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for MXCT stock is "Strong Buy." The 12-month stock price forecast is $8.67, which is an increase of 129.97% from the latest price.

Price Target

$8.67

(129.97% upside)

Analyst Consensus: Strong Buy